Form 8-K - Current report:
SEC Accession No. 0001140361-24-035799
Filing Date
2024-08-06
Accepted
2024-08-06 07:39:38
Documents
15
Period of Report
2024-08-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8K ny20030749x3_8k.htm   iXBRL 8-K 42876
2 EXHIBIT 99.1 ny20030749x3_ex99-1.htm EX-99.1 33310
6 ny20030749x3_image01.jpg GRAPHIC 29430
  Complete submission text file 0001140361-24-035799.txt   266514

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240806.xsd EX-101.SCH 3892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240806_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240806_pre.xml EX-101.PRE 16062
18 EXTRACTED XBRL INSTANCE DOCUMENT ny20030749x3_8k_htm.xml XML 4053
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 241177132
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)